Funding & Investments

Biograil closes €20m to take its swallowable injection capsule towards first human trials

The Danish biotech, which packs a drug-delivery device into a standard capsule, will use the money for safety studies and manufacturing set-up ahead of a bigger raise planned for 2027.

Author
Sandra J. Barbara
Published
Reading time
3 min read
Views
Loading views
Biograil cover image

Biograil, a Danish biotech building a capsule that delivers injectable drugs through the stomach wall, has closed a €20m financing round. The money is meant to carry its BIONDD device through the preparatory work required before a first phase 1 study in people, a step the company has been working towards since it was set up in 2019.

The round comes from investors who already know the company well. Verve Ventures and Megatrend Invest are backing it, while High-Tech Gründerfonds (HTGF), the German investor that led Biograil's seed syndicate seven years ago, returns through its later-stage vehicle, the HTGF Opportunity growth fund. The company announced the close on 4 November.

What the €20m pays for

Biograil is not yet in the clinic, and this round is not meant to get it all the way there. According to the company, the cash covers two blocks of work: non-clinical studies run under good laboratory practice (GLP), which regulators expect before a product is tested in humans, and a manufacturing process that meets good manufacturing practice (GMP) standards. Both are prerequisites for a phase 1 trial.

The company said it intends to raise a larger round in 2027. In other words, the €20m is a bridge to the point where a clinical study can be financed, rather than funding for the study itself. Biograil also counts on non-dilutive money from pharma partnerships to stretch its runway; the Australian biotech group CSL is among its partners.

Chief executive and co-founder Karsten Lindhardt said it was "excellent to see such strong support from existing internal investors and involve the HTGF Opportunity growth fund in the round." He added that the mix of equity and partnership income would let Biograil keep moving the technology towards phase 1 studies.

A pill that works like a jab

Many valuable modern drugs are biologics: proteins, peptides and antibodies that the gut breaks down before they can be absorbed. That is why patients inject them. Biograil's approach is mechanical rather than chemical. The BIONDD device sits inside an ordinary size 0 or 00 capsule, and once swallowed it places the active substance into the mucosal lining of the stomach, from where it can spread through the body.

The company sees two kinds of use. One is reformulating drugs already sold as injections, a group that includes products with sales in the billions of dollars. The other is new molecules that could never be given by mouth in the first place. Lindhardt said the platform could open the door to combination products that would not have been practical as either a conventional injection or a standard oral drug.

Manufacturing is part of the pitch. The device is made by injection moulding, a high-volume plastics process, and Biograil says members of its team previously worked on the first injection-moulded oral tablet to win approval from the US Food and Drug Administration. Lindhardt himself was previously chief scientific officer at Egalet, a drug-delivery company. He founded Biograil with Nikolaj Skak, who serves as chief scientific officer. The company is based in Roskilde, west of Copenhagen.

An investor list heavy on corporate money

For a pre-clinical company, Biograil's cap table holds an unusual number of strategic names. Alongside Megatrend Invest, Verve Ventures and HTGF, its backers include Eli Lilly, Evonik Venture Capital, Sanner Ventures, Roquette Ventures and Anobis. Having a large drugmaker on the register this early gives the device a route to industry attention before any human data exists.

Verve, founded in Switzerland in 2010, manages more than CHF 400m and invests in science-led companies from seed stage. HTGF's Opportunity fund draws its money from Germany's ERP Special Fund and from KfW, using resources of the federal Zukunftsfonds. Biograil is Danish, which makes this a case of German public-backed capital following a portfolio company across the border into a later round.

"We first invested in Biograil in 2019 because we saw the potential of its approach to oral drug delivery," said Anke Caßing, principal at HTGF.

Biograil has not published clinical data, and it did not give a date for its first trial. The next markers to watch are completion of the GLP studies, a working GMP production process, and whether the 2027 round arrives on schedule to pay for phase 1.

What did you think of this story?

Written by

Sandra J. Barbara

56 stories on European Startup Insider

Have a story like this? Pitch it to us.

We publish founder profiles, company news and practical guides from across Europe.

You’ve finished this story

Up next

Hypersonica lands €100m Series B from Lightspeed and General Catalyst to field hypersonic missiles by 2029

The Munich and London missile startup has raised €100m, roughly four times its Series A from February, to test more often, hire in the UK and Germany and reach a deep-strike capability by 2029.